Managing diabetes and its complications can be challenging, but new approaches in regenerative medicine are providing options worth exploring. At Stemedix, we offer personalized therapies that focus on supporting your body’s natural repair mechanisms. One area of growing interest is the use of MSC-derived exosomes in stem cell treatments. These tiny cellular messengers can influence how cells communicate and respond to damage, potentially benefiting those living with diabetes.
Our team works directly with your existing medical records to design therapies tailored to your condition, including specialized protocols for nerve-related complications. For individuals dealing with neuropathy, our programs incorporate stem cell therapy for diabetic neuropathy, which aims to support nerve function and improve quality of life. Through our patient-centered approach, we provide access to advanced regenerative medicine solutions for diabetes while offering guidance and care throughout your treatment journey.
The Role of MSC-Derived Exosomes in Regenerative Medicine
Cells in your body are constantly communicating to maintain balance and respond to stress, injury, or disease. Some cells release specific signals that influence how surrounding tissues react, and this process can be especially important for conditions like diabetes. By understanding these natural communication pathways, therapies can be designed to support tissue repair and improve overall cellular function.
What Are Mesenchymal Stem Cells (MSCs)?
Mesenchymal stem cells are multipotent cells capable of developing into multiple tissue types. These cells are often collected from bone marrow, adipose tissue, or umbilical cord tissue. One of the key features of MSCs is their ability to produce factors that support tissue repair and regeneration. Among these factors are exosomes, small vesicles that carry proteins, lipids, and genetic material. These exosomes interact with nearby cells, helping them respond to stress or damage.
In therapies aimed at metabolic conditions, including stem cell therapy for diabetes, MSCs provide foundational support for regenerative processes. They create an environment in which cells can recover more effectively and function with improved coordination. This cellular-level support is a critical component of patient-centered regenerative care.
How Exosomes Support Cellular Communication and Repair
Exosomes are tiny vesicles that transmit signals between cells. They carry instructions that guide how cells respond to inflammation and tissue stress. By facilitating communication among cells, exosomes help coordinate repair and maintain tissue health. In the context of regenerative therapy, exosomes are one of the primary ways stem cell treatment for diabetes may deliver its benefits. They work directly at the cellular level, helping tissues adapt and recover in response to challenges posed by metabolic disease.
At Stemedix, we focus on leveraging MSCs and their exosomes to develop personalized therapy plans tailored to your medical profile. This approach allows us to address specific concerns, including nerve-related complications, through stem cell therapy for diabetic neuropathy, while providing care designed to support overall tissue function and wellness.
Exploring the Connection Between Exosomes and Diabetes Care
Diabetes affects many aspects of how your body functions at the cellular level. Understanding these changes helps you see how regenerative therapies can provide supportive benefits and contribute to the overall management of the condition. By examining the cellular effects, it becomes clearer why therapies such as MSC-derived exosome treatments are being explored for patients living with diabetes.
The Impact of Diabetes on Cellular Function
Diabetes interferes with the body’s ability to manage blood sugar and maintain healthy cellular function. When blood glucose levels remain high over time, the cells that produce insulin may struggle to work efficiently. Blood vessel health can be compromised, and nerve function may decline, leading to symptoms such as tingling, numbness, pain, and slower wound healing. Fatigue often occurs because your cells are not receiving energy efficiently. These effects create a complex environment in your body, affecting multiple systems simultaneously. Interventions such as stem cell therapy for diabetic neuropathy aim to provide targeted support to nerve tissue and improve cellular communication, helping cells respond more effectively to stress and injury.
How MSC-Derived Exosomes May Support Pancreatic Health and Insulin Response
MSC-derived exosomes may help support pancreatic cell function and reduce inflammation. These microscopic vesicles carry proteins, lipids, and genetic material that act as messages between cells. A study demonstrated that MSC-derived exosomes improved pancreatic islet viability and enhanced insulin secretion in diabetic models by modulating inflammatory pathways and promoting cellular repair. By delivering these signals, exosomes can improve tissue conditions and promote healthier communication among cells. This activity may help pancreatic cells respond more effectively to challenges, supporting insulin production and better regulation of blood sugar. This biological signaling is an important component of stem cell solutions for diabetes and therapies designed to support long-term management of the condition, offering patients potential relief from complications related to both glucose control and nerve health.
Stem Cell Therapy for Diabetes: A Closer Look
Stem cell therapy offers a way to explore additional support for your body’s natural repair processes. By focusing on regenerative signals, this therapy aims to complement the care you already receive for diabetes.
Regenerative Mechanisms and Potential Benefits
Stem cell therapy supports the body’s natural repair mechanisms. The treatment uses MSC-derived products that interact with cells to help regulate communication and promote tissue balance. You may notice improvements in energy levels or faster recovery from wounds. Some patients also report a reduction in neuropathic discomfort, which can make daily activities more manageable. While responses differ from person to person, these therapies are grouped under stem cell treatment for diabetes, offering options for those seeking additional support in managing their condition.
At Stemedix, our approach focuses on reviewing your existing medical records and developing a personalized therapy plan tailored to your needs, helping you explore regenerative treatments safely and with guidance from experienced providers.
Stem Cell Therapy for Diabetic Neuropathy
Stem cell therapy may help manage nerve-related symptoms associated with diabetes. Exosomes, released by MSCs, carry signals that can support damaged nerve tissue and improve cellular communication. Clinical studies have shown that stem cell therapy can significantly improve nerve conduction and sensory function in diabetic neuropathy patients, supporting its potential to maintain nerve function and reduce discomfort. If you experience numbness, tingling, or weakness in your extremities, this therapy may help maintain nerve function and reduce discomfort.
Through careful evaluation and personalized care, we provide access to stem cell therapy for diabetic neuropathy, helping patients address nerve complications while maintaining a focus on comfort and practical support throughout the treatment journey.
The Stemedix Approach to Personalized Regenerative Medicine
Personalized care is at the heart of effective regenerative therapy. Each treatment plan is built around your medical history and individual needs, allowing you to feel supported throughout the process.
Individualized Treatment Design Based on Existing Medical Records
We customize treatments using patients’ existing medical documentation. You provide your current medical records, such as bloodwork, imaging studies, and MRI reports, and the team carefully reviews them to determine which therapy options may be appropriate. If any of your records are outdated, we can help gather updated information by coordinating with your healthcare providers through a signed medical release. This process allows you to move forward with a plan that reflects your specific health status. Board-certified providers then create a therapy plan designed around your needs, offering a tailored approach to stem cell therapy for diabetes and related conditions.
A Full-Service Experience in Saint Petersburg, FL
We provide support services throughout treatment to keep patients comfortable. From arranging transportation and hotel accommodations to providing mobility aids like wheelchairs or walkers, the team works to make your visit as smooth as possible. A dedicated Care Coordinator stays with you through every step, offering guidance and assistance so you always know what to expect. This attentive support extends to therapies for stem cell solutions for diabetes, giving you a coordinated and patient-focused experience.
Advancing Patient Care Through Responsible Innovation
Progress in regenerative medicine is built on careful study and patient-centered practice. You can explore therapies that use MSC-derived exosomes while being confident that your care follows ethical standards and current scientific guidance.
Research and Clinical Ethics in Regenerative Medicine
Regenerative medicine at Stemedix is conducted under strict ethical and safety standards. MSC-derived exosome therapies are considered experimental and are not approved by the FDA. This means you are participating in treatments that are still being studied, with ongoing clinical data shaping their development. Each step in the process is designed to protect your well-being while exploring potential benefits. Our approach prioritizes transparency, and you will receive clear explanations of how these therapies could work and what they aim to support in your health journey. The team evaluates research findings carefully, balancing innovation with safety so you can consider these options confidently.
What Patients Can Expect from a Stemedix Consultation
Consultations involve reviewing eligibility and therapy options based on existing records. You will provide your current medical documentation, such as lab work, imaging, or MRI results. We do not diagnose conditions or conduct physical examinations, but your records are carefully reviewed by board-certified providers who determine which therapies may be suitable for your condition. The team explains potential outcomes and walks you through each step of the treatment process. Patients exploring stem cell treatment for diabetes receive dedicated guidance and support, so they know exactly what to expect.
Begin Your Journey with Stemedix
If you are exploring stem cell solutions for diabetes, Stemedix is ready to guide you through every step of the process. Contact our team in Saint Petersburg, FL, to discuss your medical records and learn about personalized treatment options. Reach us by phone at (727) 456-8968 or email yourjourney@stemedix.com to start your consultation and receive dedicated support from our experienced Care Coordinators and board-certified providers.
Osteoarthritis (OA) is the most common form of arthritis and occurs as a result of the protective cartilage, found on the ends of the bones, degenerates over time. While OA can occur in any joint, it is most commonly found to occur in the hands, hips, spine, and knee.
An estimated 365 million people worldwide are currently living with some form of knee OA. Although there have been improvements in conventional treatment methods that have shown some benefit, there is no therapy or drug that can prevent or treat the development of OA in the knee.
Recent phase I/II trials using mesenchymal stromal cells (MSCs) derived from bone marrow (BM) and adipose tissue have demonstrated the feasibility, safety, and clinical and structural improvements in focal or diffuse disease.
Considering the findings of these phase I/II trials, Orrego et al. conducted this study to better assess the safety and efficacy of the intra-articular injection of single or repeated umbilical cord-derived (UC) MSCs in knee OA.
The target population of this study was individuals between the ages of 40-65 with symptomatic knee pain for at least 3 months with grade 1-3 Kellgren-Lawrence radiographic changes in the targeted knee, without meniscus rupture.
The authors divided participants of this study into three specific groups, a control group which received intra-articular knee injections of hyaluronic acid (HA) at baseline and 6 months; the MCS-2 group, which received UC-MSCs at baseline and 6 months; and the MSC-1 group, who received UC-MSCs at baseline followed by placebo injection at 6 months.
At the conclusion of this study’s 12 months follow-up period, Orrego et al. found that the group with repeated UC-MSC intra-articular injections, or MCS-2, experienced significant clinical changes in total WOMAC, pain component, and VAS when compared with the control group. The authors also found that only patients in the MSC groups experienced significant amelioration of pain and disability at 6 and 12 months. The authors also reported no safety signals were detected in the experimental groups as compared with the HA controls.
Considering these findings, the authors conclude that the use of MSCs produces anti-inflammatory properties in response to tissue damage or inflammation that demonstrates suppressive effects on the maturation of dendritic cells, macrophages, Natural Killer, and cytotoxic T-lymphocytes.
While these results appear promising, the authors point out that even if all MSC trials report a good safety record and improvements in cartilage quality, the use of autologous cell therapy does come with some limitations. Among these limitations include a dramatic decline of bone precursor cells when these cells are derived from bone marrow. Studies have also shown reduced chondrogenic activity of MSCs in cultures obtained from individuals with advanced forms of OA. For these reasons, and considering the findings in this study, the authors highlight that allogeneic sources of MSCs have been shown to express superior clonogenicity, migration, and paracrine capacities.
The authors conclude that the repeated UC-MSC dose strategy utilized in this study led to a favorable safety profile and improved clinical results for the treatment of long-term pain in knee OA patients.
Source: Jose Matas, Mario Orrego, Diego Amenabar, Catalina Infante, Rafael Tapia-Limonchi, Maria Ignacia Cadiz, Francisca Alcayaga-Miranda, Paz L. González, Emilio Muse, Maroun Khoury, Fernando E. Figueroa, Francisco Espinoza, Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial, Stem Cells Translational Medicine, Volume 8, Issue 3, March 2019, Pages 215–224, https://doi.org/10.1002/sctm.18-0053
Systemic lupus erythematosus (SLE) is a common multisystemic autoimmune disease that often results in multi-organ damage when left untreated. Currently affecting over 1.5 million Americans, the etiology and pathogenesis of SLE continue to remain unclear.
At present, glucocorticoids and immunosuppressants are the most prescribed course of therapeutic treatment and mostly as a way to manage and treat symptoms of SLE, not the cause itself.
Considering that the etiology and pathogenesis of SLE are accompanied by immune disorders including abnormal proliferation, differentiation, and activation and dysfunction of T cells, and that mesenchymal stem cells (MSC) and MSC-derived extracellular vesicles (EVs) play important roles in the immunity process, researchers are increasingly turning their attention to MSCs and EVs as potential therapeutic treatment options for SLE.
In this review, Yang et al. examine the immunomodulatory effects and related mechanisms of MSCs and EVs in SLE with hopes of better understanding SLE pathogenesis and guiding biological therapy.
Examining the potential use of MSC and MSC-EVs in SLE treatment the authors found some studies have established that MSCs reduce adverse effects of immunosuppressive drugs and when combined have demonstrated distinct effects on T cell activation and bias.
Additionally, Yang et al. report that MSCs are able to participate in the immune response in two distinct ways: paracrine effect and directly through cell-to-cell interaction. Since reconstruction of immune tolerance and tissue regeneration and repair are required parts of SLE treatment and since MSCs possess high self-renewal ability, rapid expansion in vitro and in vitro, and low immunogenicity, allogeneic MSC transplantation has demonstrated strong evidence for the therapeutic potential of MSC in SLE.
Besides the ability to repair and regenerate tissue, MSCs, and MSC-EVs have strong anti-inflammatory and immunomodulatory effects, making them a potentially ideal treatment option as part of a therapeutic strategy for SLE. Considering that MSC-EVs have similar biological functions with MSCs, but are also considered cell-free, the authors point out that MSC-EVs could be the better choice for SLE treatment in the future.
Despite the potential of MSC and MSC-EVs, Yang et al. point out that genetic modification, metabolic recombination, and other priming of MSCs in vitro should be considered before MSC/MSC-EVs application for SLE treatment. The authors also recommend further clinical evaluation of the time of infusion, appropriate dosage, interval of treatment, and long-term safety of MSC/MSC-EVs in the treatment of SLE before any form of the combination is used as a treatment option.
Human Mesenchymal Stem Cells (hMSCs) are the non-hematopoietic, multipotent stem cells with the capacity to differentiate into mesodermal lineages such as osteocytes, adipocytes, and chondrocytes as well ectodermal (neurocytes) and endodermal lineages (hepatocytes).
Until recently, when the immunomodulation properties of MSCs were proven to be clinically relevant, the use of these stem cells was met with skepticism and doubt by a large portion of the scientific community.
However, since that time, MSCs have demonstrated tremendous potential for allogeneic use in a number of applications, including cell replacement, and tissue regeneration, and for use in the therapeutic treatment of immune- and inflammation-mediated diseases. In fact, in many cases, the use of MSCs has been so successful that they appear to demonstrate more efficacy than what has been observed previously in traditional regenerative medicine.
Among the many benefits making MSCs so interesting for this application is their capacity for both multilineage differentiation and immunomodulation. Obtaining a better understanding of these capacities has opened new doors in regenerative medicine and demonstrated that these somatic progenitor cells are highly versatile for a wide range of therapeutic applications.
Additionally, the authors of this review point to research indicating the capacity of MSCs to home to the site of injury and/or inflammation, making them more attractive for use in clinical application. In this review, Wang et al. focus on this non-traditional clinical use of tissue-specific stem cells and highlight important findings and trends in this exciting area of stem cell therapy.
At the time this review was published, there were over 500 MSCs-related studies registered with the NIH Clinical Trial Database. Interestingly, nearly half of these trials involve attempts to better understand the use of MSCs in treating immune- and inflammation-mediated diseases – an indication of the recent shift in focus when determining effective therapeutic applications of MSCs.
In reviewing these clinical trials, Wang et al. found that the most common immune-/inflammation-mediated indications in MSC clinical trials were for graft-versus-host disease (GVHD), osteoarthritis (OA), obstructive airway disease, multiple sclerosis (MS), and solid organ transplant rejection.
Clinical trials involving MSCs, and specifically HSCs, in GVHD have indicated that while there may be indications of immunosuppressant therapy, immune rejection in the form of GVHD is still a major cause of morbidity and mortality, occurring in 30 ~ 40 % of allogeneic HSC transplantations.
Despite a number of clinical trials indicating significant efficacy in the use of MSCs for GVHD treatment, the authors point out that these findings were not observed consistently throughout all trials. Significant differences in these studies appeared to be related to differences in adult and pediatric applications, a specific type of HSC that was transplanted, and the type of MSCs that were utilized. There also appears to be a disparity in the results obtained from similar studies conducted in Europe and North America. Considering this, there are a number of studies involving MSCs and GVHD still ongoing.
These findings led the authors to conclude that despite the strong potential of MSCs as therapeutic agents for GVHD, detailed tailoring of the patient population and stringent MSC processing criteria are necessary to deliver consistent and reproducible results.
Despite the mixed findings for use of MSCs in the treatment of GVHD, trials reviewed for other immune/inflammation-mediated diseases, including MS, inflammatory bowel disease, OA, RA, and inflammatory airway and pulmonary diseases demonstrated positive results pertaining to the safety of MSC therapy when used in this application.
Specifically, Wang et al. point out that although there have been positive results observed in preclinical animal studies, these results have not translated to clinical efficacy. In considering this, the authors suggest a focus on better clarifying pathophysiological details and subsets within disease entities to better tailor MSC therapy and standardization of in vitro culture protocols with stringent criteria for testing of functional parameters as two important steps to improve our understanding on the mechanistic properties of MSC immunomodulation.
Despite these recommendations, the authors conclude that the current results and developments of these clinical trials demonstrate that the tremendous potential of MSC therapy in a wide range of areas, including the treatment of immune/inflammation-mediated diseases, can be expected in the near future to achieve clinical relevance. Source: “Human mesenchymal stem cells (MSCs) for treatment towards ….” 4 Nov. 2016, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095977/.
Multiple system atrophy (MSA) is a rare, degenerative adult-onset neurological disorder that affects your body’s involuntary functions, including blood pressure, breathing, bladder function, and motor control. MSA also demonstrates several symptoms similar to those accompanying Parkinson’s disease, including slow movement, stiff muscles, and loss of balance[1].
Considering the rapid and fatal progression of MSA, there are not currently any long-term drug treatments known to produce therapeutic benefits against the condition. The typical neuropathological hallmarks of MSA are bone marrow destruction and cell loss in the striatonigral region of the brain that results in dopamine deficiency significant enough to result in behavioral abnormalities.
Since mesenchymal stem cells (MSCs) have demonstrated the ability to self-renew and differentiate within a wide variety of tissues, Park et al., in this study, aimed to assess whether the transplantation of human-derived MSCs could have beneficial effects in a double-toxin-induced MSA rat model. Additionally, the authors assessed the signaling-based mechanisms underlying the neuroprotective effects of MSCs.
Specifically, as part of this study, Park et al. studied the effects of MSCs in 60 rats randomly allocated to one of six groups – a control group, a double-toxin group, two groups receiving MSC intra-arterial (IA) injections, and two groups receiving MSC transplantation via intrathecal (IT) injection after double-toxin induction.
After receiving treatment each group of rats underwent a variety of tests, including the Rotarod test, gait test, and grip strength test. Additionally, the brain tissue of the rats was collected, preserved, and evaluated to assess notable differences.
At the conclusion of this study, the authors found clear evidence of the protective effects of MSCs on double-toxin-induced MSA. The study also demonstrated that transplantation of MSCs prevented neuronal cell death and improved behavioral disorders caused by double-toxin-induced MSA, specifically by reducing dopaminergic neurodegeneration and neuroinflammation.
Additionally, Park et al.’s study demonstrated a higher expression of polyamine modulating factor-binding protein 1 and a lower expression of 3-hydroxymethyl-3-methylglutaryl-COA lyase (HMGCL) after MSC transplantation.
Park et al. also point out that further investigation is required to better understand the exact mechanism of neuron-specific knockdown in vivo animal and clinical trials.
The authors of this study conclude that treating MSA with bone-marrow-derived MSCs protects against neuronal loss by reducing polyamine- and cholesterol-induced neural damage and may represent a promising new therapeutic treatment option for MSA.
This website and its contents are not intended to treat, cure, diagnose, or prevent any disease. Stemedix, Inc. shall not be held liable for the medical claims made by patient testimonials or videos. They are not to be viewed as a guarantee for each individual. The efficacy for some products presented have not been confirmed by the Food and Drug Administration (FDA).
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
Subscribe To Our Newsletter
Join our mailing list to receive the latest news and updates from our team.
You have Successfully Subscribed!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
Thanks for your interest!
Request Information Packet
We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!
St. Petersburg, Florida
